Synaptogenix announces regenerative patent award to treat alzheimer's disease

New york, july 7, 2021 /prnewswire/ -- synaptogenix, inc. (nasdaq: snpx), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that a new patent has been awarded by the u.s. patent and trademark office. patent number 16/914,399 is entitled: methods for inducing synaptogenesis with synaptic growth factor activating compounds.
SNPX Ratings Summary
SNPX Quant Ranking